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CASE REPORT
Rash associated with Pregabalin: A case report
Pregabalin ilişkili döküntü: Olgu sunumu
Burak Uz1, Ali Alkan2, Hakan Göker1, Nilgün Atakan3, Osman İlhami Özcebe1
ÖZET
Kırksekiz yaşında ve 2 aydır nöropati tedavisi için 300 
mg/gün oral yolla pregabalin kullanan erkek hasta, eks-
tremiteler ve lomber bölgesinde eritematöz, makülopapü-
ler döküntü şikayeti ile başvurdu. Naranjo olasılık skalası 
döküntü ve pregabalin kullanımı arasında muhtemel bir 
ilişkiyi gösterdi. Pregabalin tedavisi kesilerek, antihistami-
nik tedavi, oral metilprednizolon ve topical steroidli krem 
başlandı. Tedavinin kesilmesinden 1 hafta sonra döküntü 
neredeyse tamamen düzeldi. Pregabalin ilişkili döküntü 
faz 3 klinik çalışmalarda nadiren rapor edilmiştir. Prega-
balin kullanımına eşlik eden döküntü daha önce yalnızca 
bir vaka raporunda sunulmuştur. Pregabalin ilişkili dökün-
tünün mekanizması tam olarak anlaşılamamıştır. Düşük 
dozlarda pregabalin tedavisine başlamak ve doz artımını 
yavaş yapmak yan etki insidansını azaltabilir.
Anahtar kelimeler: pregabalin, döküntü, multipl myelom
ABSTRACT
A  48-year-old  man  with  erythematous,  maculopapular 
rash localized to his extremities and lumbar region that 
he had been receiving oral pregabalin 300 mg per day for 
2 months to treat his neuropathy was applied. The Nara-
njo probability scale indicates a probable relationship be-
tween the development of rash and use of pregabalin by 
our patient. Pregabalin was discontinued and antihista-
minic treatment, oral methyprednisolone and topical ste-
roid cream were given to treat the rash. The rash almost 
completely resolved one week after pregabalin was dis-
continued. Pregabalin-induced rash was rarely reported 
in Phase 3 clinical trials, and there is currently only one 
available report on the development of a rash coinciding 
with the use of pregabalin. No clear mechanisms reported 
for rash associated with pregabalin. It is usually recom-
mended to start pregabalin with low doses and slow in-
creases might prevent the incidence of side effects. J Clin 
Exp Invest 2013; 4 (1): 107-109
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INTRODUCTION
Pregabalin  is  a  new  synthetic  analog  of 
γ-aminobutyric acid. The precise mode of action of 
pregabalin has not been fully elucidated; it possibly 
does  interact  with  α2δ  presynaptic  voltage  gated 
calcium channels and reduces the release of sev-
eral neurotransmitters.1 It’s approved for the treat-
ment of neuropathic pain associated with diabetic 
peripheral neuropathy, and postherpetic neuralgia.
Pregabalin is generally well tolerated. It’s side 
effects  are  usually  mild-to-moderate  in  intensity 
and are usually transient.1 Dizziness and somno-
lence are the most frequent adverse reactions for 
drug withdrawal.2 The discontinuation rate due to 
adverse events varies across studies, but it is ap-
proximately 17% for patients receiving pregabalin 
(depending on dose) compared to 6.3% for patients 
receiving placebo.3
The adverse effect profiles of most antiepilep-
tic drugs include rash. Gabapentin, an antiepileptic 
drug used in neuropathic pain, may cause rash dur-
ing treatment.4,5 Because of the similar molecular 
structure with pregabalin, hypersensitivity reactions 
can possibly be observed during pregabalin treat-
ment. However, we could find only one published 
report in describing the development of rash due to 
Pregabalin.6 Herein, we present a second patient 
who developed an extensive rash one week after 
beginning pregabalin therapy for neuropathy.Uz et al. Rash associated with Pregabalin 108
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CASE
A  48-year-old  man  presented  with  malaise  and 
backache. Anemia and increased erytrocyte sedi-
mentation rate was noted. Bone scan showed os-
teolytic  lesions  on  the  clavicula,  right  radius  and 
9th-10th ribs. Evaluation for the suspicion of multipl 
myeloma showed light chain kappa in serum and 
urinary protein electrophoresis. Diffuse neoplastic 
plasma cell infiltration was documented in the bone 
marrow biopsy and aspiration. After the diagnosis of 
multipl myeloma, then the patient was treated with 
vincristine 0.4 mg, adriamycin 9 mg/m2 and dexa-
methasone 40 mg (VAD) chemotherapy. After 2 cy-
cles of VAD chemotherapy, he received bortezomib 
1.3 mg/m2, adriamycin 9 mg/m2, dexamethasone 
40 mg (PAD). After 4 cycles of PAD chemotherapy, 
the patient received autologous bone marrow trans-
plantation on October 2010.
Figure 1. Bilateral palmar eritematous rash
After  his  chemotherapy  regimen,  the  patient 
developed  palmar-plantar  pain  and  hypoesthe-
sia.  In  neurological  evaluation,  electromyography 
showed  mild  polyneuropathy  with axonal  involve-
ment of the sensory neurons. The polyneuropathy 
was probably associated with vincristin therapy and 
the patient was than treated with pregabalin (Lyrica, 
Pfizer). The starting dose was 150 mg po daily and 
increased gradually to 300 mg daily. Initially there 
were no adverse effects. However, on the 7th day 
of treatment, a maculopapular rash, without itching, 
has started, then increased, and spread over his 
wrist and progressed to the proximal arm and palms 
(Figure 1). Rash also occured over the lumbar re-
gion and proximal thigh (Figure 2). No mucosal le-
sion was seen. After dermatological evaluation, the 
rash was associated with recently started drug, pre-
gabalin. Pregabalin was then discontinued and sys-
temic antihistaminic treatment, methylprednisolone 
(20 mg/day, for 10 days) and topical steroid cream 
2-3 times daily were initiated. His rash over the lum-
bar region and proximal arm abruptly disappeared. 
Rash over the wrist completely resolved over one 
week period. After symptomatic relief, as an alter-
native  therapy  for  the  ongoing  neuropathic  pain, 
gabapentin was initiated 300 mg po daily. During 1 
month follow-up, similar allergic reactions were not 
encountered and neurological visit showed clinical 
improvement.
Figure 2. Maculopapular rash on the trunk and lumbar 
area
DISCUSSION
Numerous  factors  that  may  increase  the  propen-
sity of an individual to develop a drug-induced rash 
have  been  identified.  These  factors  are,  being  a 
woman of child-bearing age, the initial dose select-
ed,  concomitant  viral  infection,  immune-mediated 
disorders, pharmacogenetic variability, and age.7,8 
Arif et al. emphasized that the only non-drug predic-
tor of antiepileptic drug (AED) related rash was rash 
to another AED, with an odds ratio of 3.1.4 This pa-
tient had a hematologic malignancy which at least 
in partly may have contributed to the development 
of rash via immune mechanisms. As a precaution, 
pregabalin treatment was started with lower doses 
(150 mg) and increased to recommended dose (300 
mg). Due to his medications for multiple myeloma 
including, prophylactic antibiotics (levofloxacin, tri-
methoprim/sulfamethoxasole), calcium plus vitamin 
D3, zoledronic acid and proton pump inhibitor, it’s 
difficult to definitively attribute the rash to pregaba-
lin treatment. The Naranjo Adverse Drug Reaction 
Probability Scale is a simple questionnaire includ-
ing10 parameters for determining the likelihood of 
whether an adverse drug reaction is actually due Uz et al. Rash associated with Pregabalin 109
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to the drug rather than the result of other factors. 
Probability is assigned via a score termed definite, 
probable, possible or doubtful.9 Using the Naranjo 
Scale, a ‘‘probable’’ reaction (Score: 6) was attrib-
uted to pregabalin.
The nature and etiology of a drug-induced rash 
may vary depending on the patient and the agent. 
The most common drug-induced rash is erythema-
tous and is usually a result of delayed cell-mediated 
hypersensitivity. This occurs after the first or sec-
ond week of therapy.10 In our patient, more common 
complaints such as dizziness and somnolence were 
not encountered. On the sevent day of pregabalin 
treatment, erythematous rash located on his upper 
extremities, lumbar region and proximal thigh. With-
drawal of drug and symptomatic medication led to 
dramatic reduction of the mentioned lesions. Smith 
et al.6 reported that, in their patient, the onset of the 
rash was approximately 2 days after beginning of 
pregabalin treatment, which was much earlier than 
our patient.
The  efficacy  and  safety  of  pregabalin  in  the 
treatment  of  neuropathic  pain  was  assessed  in 
three  large  randomized  controlled  trials.  In  a  six 
week  study  of  246  patients  receiving  pregabalin 
150 mg, 600 mg, or placebo; overall pregabalin was 
found to be well tolerated.11 The most common side-
effects reported in both pregabalin treatment arms 
were dizziness and somnolence. Two other large 
clinical trials reported similar side-effect profiles.12,13 
More recently, a randomized, double-blind, placebo 
controlled trial showed that pregabalin (600 mg/day) 
was  well-tolerated,  and  the  adverse  events  were 
higher  in  the  pregabalin  arm. The  most  common 
adverse events due to pregabalin were, peripheral 
edema, dizziness, weight gain and somnolence.14
In  this  patient,  after  noting  rash,  pregabalin 
treatment was stopped immediately. After resolution 
of symptoms, gabapentin was started at lower dos-
es and followed cautiously. However, no adverse 
effects were observed with gabapentin treatment. 
This may be due to the fact that, the S-isomer of 
the pregabalin has approximately 10 times higher 
affinity for the alpha-2-delta site which is required 
for anticonvulsant activity of pregabalin in vivo than 
the R-isomer.15
Like  other  numerous  drugs,  adverse  effects 
can also be seen with pregabalin treatment. Rash, 
relatively  a  rare  complication  of  pregabalin  treat-
ment, must be further investigated for its nature and 
cross reactivity with other drugs.
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